Advaxis Inc. (NASDAQ:ADXS)’s share price fell 5.2% during mid-day trading on Tuesday . The company traded as low as $13.33 and last traded at $13.45, with a volume of 969,526 shares traded. The stock had previously closed at $14.19.

A number of brokerages have issued reports on ADXS. FBR & Co restated an “outperform” rating and set a $34.00 target price on shares of Advaxis in a report on Thursday, July 7th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Advaxis in a report on Thursday, June 9th. Barclays PLC raised their target price on Advaxis from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, August 3rd. Finally, Jefferies Group restated a “buy” rating on shares of Advaxis in a report on Friday, June 10th. Six investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $25.80.

The firm’s market cap is $416.96 million. The firm’s 50-day moving average is $10.87 and its 200-day moving average is $8.82.

In other Advaxis news, Director David Sidransky sold 22,808 shares of the company’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total value of $342,348.08. Following the completion of the transaction, the director now owns 91,759 shares of the company’s stock, valued at approximately $1,377,302.59. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard J. Berman sold 18,000 shares of the company’s stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $15.21, for a total value of $273,780.00. Following the completion of the transaction, the director now directly owns 66,430 shares of the company’s stock, valued at approximately $1,010,400.30. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.